Disease/Infection News

RSS

Researchers assess impact of coronavirus disease on individuals with progressive multiple sclerosis

Researchers conducting a large international study of progressive multiple sclerosis (MS) examined the impact of the global outbreak of coronavirus disease 2019 (COVID-19) on their study participants.

3 Sep 2020

Antibody responses in recovered COVID-19 individuals from India

India has been hit hard by COVID-19, with at least 66,000 deaths and almost 4 million cases. The need to understand the infection, including the various antibody isotypes, and whether neutralizing antibodies and memory B cells are being produced, has driven much research into the way immunity is developing in Indian patients.

3 Sep 2020

A global study to determine COVID-19 health and psychosocial consequences

The current paper lays out the details of a longitudinal study that aims to follow up COVID-19 patients, including any pre-existing chronic illnesses as well as the medical care they received during their illness. A significant minority of convalescents appears to have prolonged disease sequelae.

3 Sep 2020

Major UK study launched to assess the impact of COVID-19 on cancer patients

A new UK study has been launched to assess the impact of covid-19 on people with cancer.

2 Sep 2020

VUMC launches clinical trial of promising COVID-19 treatments in outpatient setting

Vanderbilt University Medical Center is launching a clinical trial of promising treatments for COVID-19 in the outpatient setting.

2 Sep 2020

UC San Diego participates in second, massive clinical trial of COVID-19 vaccine

UC San Diego Health will be part of a second, massive clinical trial to assess the safety, efficacy and immunogenicity of a vaccine designed to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

2 Sep 2020

Depression symptoms have tripled during COVID-19 pandemic, finds study

A first-of-its-kind study from the Boston University School of Public Health (BUSPH) finds 27.8% of U.S. adults had depression symptoms as of mid-April, compared to 8.5% before the COVID-19 pandemic.

2 Sep 2020

Combined point-of-care nucleic acid and antibody testing increases COVID-19 detection

A Cambridge hospital has piloted the use of combined rapid point-of-care nucleic acid and antibody testing for SARS-CoV-2 infection after researchers at the University of Cambridge showed that this approach was superior to virus detection alone for diagnosing COVID-19 disease.

2 Sep 2020

Study shows SARS-CoV-2 jumps back and forth between animals and humans on mink farms

An in-depth investigation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks on 16 mink farms by researchers from the Netherlands revealed that minks might serve as a reservoir for persistent infection in humans. The study is currently available on bioRxiv* preprint server.

2 Sep 2020

Treating critically ill COVID-19 patients with steroid improves chances of recovery

A new international study published today [02 September] has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery.

2 Sep 2020

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

The National Institutes of Health today announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of its Rapid Acceleration of Diagnostics (RADx) initiative.

2 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Brazilian state of Maranhão heading towards SARS-CoV-2 herd immunity, say researchers

Researchers at the Federal University of Maranhão, Brazil, have conducted a study suggesting that the state of Maranhão is well on its way to acquiring herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Doubts cast over use of face shields, masks with valves against SARS-CoV-2

Many countries across the globe are experiencing a sharp surge in COVID-19 cases, with the total global case toll reaching more than 25.86 million. Face masks have become one of the most effective means to combat the virus spread, particularly if used in combination with regular hand hygiene and physical distancing.

2 Sep 2020

New emergency program provides mental health care across Colorado

The COVID-19 pandemic's effects run deep - far beyond the virus's immediate infections. From loss of livelihoods to drastic decreases in social connection, people across the country are suffering ongoing emotional strain.

2 Sep 2020

Scientists identify potential blood-clotting mechanism in COVID-19

Why so many COVID-19 patients get blood clots (thrombosis) remains uncertain. But scientists at Uppsala University and the University Hospital have now identified a mechanism they believe to be implicated.

2 Sep 2020

Blood test can identify patients at high risk of severe COVID-19

A blood test on hospital admission showing the presence or absence of SARS-CoV-2 can identify patients at a high risk of severe COVID-19.

2 Sep 2020

Health officials worry nation is not ready for COVID-19 vaccine

Millions of Americans are counting on a COVID-19 vaccine to curb the global pandemic and return life to normal.

2 Sep 2020

Novel technique to detect the fungus responsible for causing severe pneumonia

Research staff of the University of Valencia and the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community, among other institutions, have developed a very sensitive and fast in-vitro method for the diagnosis of infection by Pneumocystis jirovecii, a fungus that causes severe pneumonia.

2 Sep 2020

Durable IgG antibodies to SARS-CoV-2 from the Iceland experience

Now, a team of scientists at the Reykjavik-based deCODe Genetics, a subsidiary of the U.S. biotech company Amgen, and several universities and hospitals in Iceland, says that the antibodies developed to fight SARS-CoV-2 last for at least four months and do not fade quickly as previously thought.

2 Sep 2020